Syndax Pharmaceuticals (SNDX)

Executive Summary

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for difficult-to-treat cancers. The company has one approved product, axatilimab (a CSF-1R antibody) for chronic graft-versus-host disease (cGVHD), and a pipeline of 37 drug candidates, including revumenib (a menin inhibitor) for NPM1-mutant acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL), and axatilimab for idiopathic pulmonary fibrosis (IPF). Revumenib has demonstrated promising efficacy in early trials and received breakthrough therapy designation from the FDA. The company also has early-stage BET inhibitors and other programs. With a strong focus on hematologic malignancies and solid tumors, Syndax is positioned to address high unmet medical needs. The upcoming catalysts include regulatory decisions, pivotal trial readouts, and pipeline expansions that could significantly impact the company's valuation and commercial prospects.

Upcoming Catalysts (preview)

• H2 2026Revumenib NDA submission and FDA decision for NPM1-mutant AML75% success
• Q4 2026Axatilimab Phase 2 top-line data in idiopathic pulmonary fibrosis40% success
• H1 2026Revumenib combination therapy data in AML60% success